Evidence map›Paper›PMID 35752436›Full record

ArticleThe journal of allergy and clinical immunology. In practice2022

SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.

Andriana I Papaioannou, Evangelia Fouka, Nikolaos Tzanakis, Katerina Antoniou, Konstantinos Samitas, Eleftherios Zervas, Konstantinos Kostikas, Konstantinos Bartziokas, Konstantinos Porpodis, Despoina Papakosta and 29 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Clinical features in patients with COVID-19 treated with biologics for severe asthma.The journal of allergy and clinical immunology. Global · 2024
    Article
  5. Article
  6. Treating asthma in the time of COVID.The Journal of allergy and clinical immunology · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 12 institutions in 1 country.

Andriana I Papaioannou2nd Respiratory Medicine Department, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: papaioannouandriana@gmail.com.
Evangelia FoukaPulmonary Department, General Hospital G. Papanikolaou, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Nikolaos TzanakisDepartment of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
Katerina AntoniouDepartment of Thoracic Medicine, Heraklion University Hospital, Medical School, University of Crete, Heraklion, Greece.
Konstantinos Samitas7th Respiratory Medicine Department and Asthma Center, Athens Chest Hospital "Sotiria", Athens, Greece.
Eleftherios Zervas7th Respiratory Medicine Department and Asthma Center, Athens Chest Hospital "Sotiria", Athens, Greece.
Konstantinos KostikasRespiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greece.
Konstantinos BartziokasRespiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greece.
Konstantinos PorpodisPulmonary Department, General Hospital G. Papanikolaou, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Despoina PapakostaPulmonary Department, General Hospital G. Papanikolaou, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Argyris TzouvelekisDepartment of Respiratory and Internal Medicine, University of Patras Faculty of Medicine, Patras, Greece.
Irini GerogianniDepartment of Respiratory Medicine, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Ourania KotsiouDepartment of Respiratory Medicine, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Michael MakrisAllergy Unit, 2nd Department of Dermatology and Venereology, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Nikoletta Rovina1st Department of Pulmonary Medicine and Intensive Care Unit, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Garyfallia VlachouRespiratory Medicine Department, General Hospital of Tripolis, Tripolis, Greece.
Miltiadis MarkatosHeraklion, Greece.
Stelios VittorakisChania, Greece.
Konstantinos KatsoulisPulmonary Department, 424 Army General Hospital, Periferiaki Odos, Efkarpia, Thessaloniki, Greece.
Ilias PapanikolaouPulmonary Department, Corfu General Hospital, Corfu, Greece.
Andreas AfthinosPulmonary Department, Corfu General Hospital, Corfu, Greece.
Paraskevi KatsaounouPulmonary and Respiratory Failure Department, First ICU, Evaggelismos Hospital, Athens, Greece.
Paschalis SteiropoulosDepartment of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Dimitrios LatsiosDrama, Greece.
Katerina Dimakou5th Pulmonary Department, "Sotiria" Chest Hospital, Athens, Greece.
Sofia Koukidou5th Pulmonary Department, "Sotiria" Chest Hospital, Athens, Greece.
Georgios Hillas5th Pulmonary Department, "Sotiria" Chest Hospital, Athens, Greece.
Stavros TryfonNHS Pulmonary Department, G.H. "G. Papanikolaou", Thessaloniki, Greece.
Maria Kallieri2nd Respiratory Medicine Department, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Athina Georgopoulou1st Department of Pulmonary Medicine and Intensive Care Unit, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Pantelis AvarlisKalamata, Greece.
Petros Bakakos1st Department of Pulmonary Medicine and Intensive Care Unit, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Katerina MarkopoulouNHS Pulmonary Department, G.H. "G. Papanikolaou", Thessaloniki, Greece.
Eleni GakiTrikala, Greece.
Asimina PaspalaThessaloniki, Greece.
Zacharoula KyriakakiAthens, Greece.
Konstantinos I GourgoulianisDepartment of Respiratory Medicine, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Spyridon Papiris2nd Respiratory Medicine Department, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Stelios Loukides2nd Respiratory Medicine Department, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRSotiria General Hospital · GRAristotle University of Thessaloniki · GRUniversity of Thessaly · GRCorfu General Clinic · GRG. Papanikolaou General Hospital · GRUniversity of Crete · GRUniversity of Ioannina · GR424 General Military Hospital · GRDemocritus University of Thrace · GREvangelismos Hospital · GRUniversity of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics.

objectiveTo prospectively observe a cohort of severe asthmatics treated with biologics for the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease severity during the COVID-19 pandemic.

methodsPhysicians from centers treating patients with severe asthma all over Greece provided demographic and medical data regarding their patients treated with biologics. Physicians were also asked to follow up patients during the pandemic and to perform a polymerase chain reaction test in case of a suspected SARS-Cov-2 infection.

resultsAmong the 591 severe asthmatics (63.5% female) included in the study, 219 (37.1%) were treated with omalizumab, 358 (60.6%) with mepolizumab, and 14 (2.4%) with benralizumab. In total, 26 patients (4.4%) had a confirmed SARS-CoV-2 infection, 9 (34.6%) of whom were admitted to the hospital because of severe COVID-19, and 1 required mechanical ventilation and died 19 days after admission. Of the 26 infected patients, 5 (19.2%) experienced asthma control deterioration, characterized as exacerbation that required treatment with systemic corticosteroids. The scheduled administration of the biological therapy was performed timely in all patients with the exception of 2, in whom it was postponed for 1 week according to their doctors' suggestion.

conclusionOur study confirms that despite the initial concerns, SARS-CoV-2 infection is not more common in asthmatics treated with biologics compared with the general population, whereas the use of biologic treatments for severe asthma during the COVID-19 pandemic does not seem to be related to adverse outcomes from severe COVID-19.

Indexed as

AsthmaBiological ProductsCOVID-19Adrenal Cortex HormonesFemaleHumansMaleOmalizumabPandemicsSARS-CoV-2Adrenal Cortex HormonesBiological ProductsOmalizumabBenralizumabBiologicsCOVID-19ExacerbationMepolizumabOmalizumabSARS-CoV-2Severe asthma

Identifiers

PMID35752436
PMCPMC9222651
OpenAlexW4283311652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.